ORYZON to participate in upcoming events in February and March

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:

Bio-Neuroscience 2026, February 24-27
Location: Hotel Jakarta, Amsterdam

SmallCap Event 20th Edition, March 17
Location: Les Salons Hoche, Paris

BIO-Europe Spring 2026, March 23-25
Location: Feira Internacional de Lisboa (FIL), Lisbon

LSX World Congress Europe, March 25-26
Location: Lisbon Congress Centre, Lisbon
Presentation type: Panel Discussion
Presentation date and time: March 25, 14:00 GMT

Oryzon management will be available for one-on-one meetings during the conferences.

About Oryzon

Founded in 2000 and headquartered in Barcelona, Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology. Oryzon’s team comprises highly experienced pharmaceutical professionals based in Barcelona, Boston, and New Jersey. The Company has an advanced clinical portfolio built around two LSD1 inhibitors: vafidemstat, its lead CNS program, which is Phase III–ready; and iadademstat, its oncology/hematology program, with several ongoing Phase I and II studies and outstanding preliminary results in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented at ASH 2025. In addition, Oryzon is advancing a broader epigenetics pipeline targeting other mechanisms, including HDAC6, for which a clinical candidate, ORY-4001, has been nominated for potential development in Charcot–Marie–Tooth disease (CMT) and amyotrophic lateral sclerosis (ALS). The Company also operates a robust platform for biomarker identification and target validation across a range of malignant and neurological diseases. For more information, visit www.oryzon.com